Grail Shares Rally on Favorable FDA Staff Review

US FDA staff reviewers raised no major safety or accuracy concerns regarding Grails Galleri multi-cancer blood test. The positive preliminary findings sent company shares surging ahead of an upcoming advisory committee meeting.

Xurve View
Insights:
FILE PHOTO: Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020.

GRAIL INC shares surged 35% on Monday after United States regulators flagged no major accuracy or safety concerns for its multi-cancer blood test. The findings arrived ahead of an external panel review on Wednesday regarding premarket approval for the screening tool. Grail's test generated $136.8M in revenue across the country last year.